Navigation Links
Forterus Inc. Treatment Centers Showing Consistent, Sustainable Growth; CEO Paul Howarth Interviewed
Date:9/2/2009

MURRIETA, Calif., Sept. 2 /PRNewswire-FirstCall/ -- Forterus Inc. (Pink Sheets: FTER), which, through its ABTTC Inc. division, provides drug and alcohol rehabilitation and a variety of other behavioral healthcare services with the highest levels of accreditation, announced today that its co-founder and CEO, Paul Howarth, was interviewed by analyst Francis Gaskin on the Company's recent successes, management team and shareholder relations.

The complete interview is available at http://www.stoxrox.com/fter-9-1-09-voice.mp3.

"We are becoming one of the largest drug and alcohol rehabilitation and treatment centers in Southern California," Mr. Howarth said. "With capacity and near capacity at our centers, we are reaping the success of our recent marketing efforts. Also, in this economy, we are seeing a trend away from the centers for the rich and famous and toward our facilities that provide equally excellent services at a more affordable price."

"We have 30-40 success stories every month with our 28-90 day in-patient residential, community-based treatment centers. It's an exciting and very rewarding business to be in," Forterus' CEO said in the Gaskins interview.

Mr. Howarth also said that he and Jerrod Menz, Forterus Vice President and President of its "A Better Tomorrow" facility, have recently signed employment contracts for the next five years. "I believe it sends the right message to our shareholders that we are continuing with the Company." Mr. Howarth also said the Company is initiating a buyback plan to retire some of its outstanding common shares.

"We believe in consistent, sustainable growth. We are very pleased with our shareholders who have stayed with the Company and are now gaining significant rewards," Mr. How
'/>"/>

SOURCE Forterus Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Forterus Inc. Posts Revenue, Net Income Gains
2. Forterus Inc. Elects Jeff Walton, Former Bear Stearns President, to Board of Directors; Applying to Open New Facility near Los Angeles
3. Forterus Inc. Treatment Centers Serving Middle-Class; Rapid Growth Detailed in Paul Howarth Interview
4. Forterus Inc. Announces Special Board Meeting; Nominates Jeff Walton, Former Bear Stearns President, to Board of Directors
5. Forterus Inc. Announces Free Outpatient Treatment to Military Veterans Back from War Zones
6. Advertisement for Forterus Treatment Center, A Better Tomorrow, Featured on A & E Network
7. Forterus Treatment Center, A Better Tomorrow, Featured in Major Network Program
8. A Better Tomorrow Treatment Center Inc., a Forterus Subsidiary, to Be Featured On A & E Television Networks Intervention Program
9. Forterus Healthcare Continues Its Southern California Expansion, Completing Its Second Acquisition in Six Months
10. Forterus Healthcare to Acquire Solutions 4 Recovery
11. Forterus Inc. Announces Stock Buyback

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)...linical trial presented today at the annual meetin...NA) provide the first strong evidence of the benef...ense breasts who are at elevated risk for breast c...s highly sensitive in depicting early breast cance...ound in addition to mammography significantly impr...
(Date:12/1/2009)...RNewswire/ -- Reportlinker.com announces that a ne...ogue: ,, The Future of Central Nervous System ...Competitive Benchmarking, Product Pipeline and Dea...166814/The-Future-of-Central-Nervous-System-Diseas...tive-Benchmarking-Product-Pipeline-and-Deals-Analy...
(Date:12/1/2009)...wire-USNewswire/ -- The Kerlan Jobe Orthopaedic Cl... agreed to pay the United States $3 million to set... from HealthSouth Corporation, the Justice Departm...olves allegations that HealthSouth paid kickbacks ... donations to the Kerlan Jobe Foundation, loan for...
(Date:12/1/2009)...rths more likely, British study finds , ,...en who are poor are more likely to deliver a very ... both groups typically receive equal care, a new B...er research team said their findings show the need...mic status and preterm birth. , For the study, ...
(Date:12/1/2009)...ation Changes Name to HealthHIV , ...ation, one of the largest national HIV non-profit ...nd launching a new website. The announcement on Wo...n to promote the organization’s new vision a...uo;HealthHIV clearly, quickly and easily states ou...
Breaking Medicine News(10 mins):Health News:Annual screening with breast ultrasound or MRI could benefit some women 2Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 2Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 3Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 4Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 5Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 6Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 7Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 8Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 9Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 10Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 11Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 12Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 13Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 14Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 15Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 16Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 17Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 18Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 19Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 20Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 21Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 22Health News:Los Angeles' Kerlan Jobe Orthopaedic Clinic Pays $3 Million to Settle Kickback Allegations 2Health News:More Preemies Born Among the Poor 2Health News:National HIV Non-Profit Announces New Name 2
... cancer is currently one of the most common male c...h in men.// Findings from a recent study suggests ... The study, conducted in a mouse model of human p...ke, growth-factor-driven pathway present in prosta...
...udy shows that low low-density lipoprotein, also k... by 10 percent // thereby improving the relative a...et that includes between eight and 10 walnuts a da...betes. A team of dieticians developed individua...
... ablation is a non-surgical technique used to elim...se abnormal heartbeats. // Researchers now say tha...atrial fibrillation a type of irregular heart rhyt...re who were undergoing catheter ablation for atria...
...ion to being at-risk for various health conditions... being accurately diagnosed // during medical imag...y obesity can limit the ability and accuracy of im... nearly doubled from 0.10 percent to 0.19 percent ...
... study shows chronic back pain shrinks the brain ...he degeneration of 10 to 20 years of aging.// ...tomated analysis techniques, researchers compared ...in for more than one year. The study showed tha...
...udy suggests young people are more likely to becom...form of a gene // that helps clear nicotine out of... CYP2A6 gene were about three-times more likely to...igarettes. In a study, carried out among seventh g...
Other Medicine News:
(Date:12/1/2009)...swire-FirstCall/ -- CEL-SCI Corporation (NYSE Amex...loper of vaccines and therapeutics for the prevent...d today that it has retained the services of an in...o run CEL-SCI,s upcoming Phase III clinical trial ...Company,s lead product candidate, Multikine®....
(Date:12/1/2009)...PRNewswire/ -- Sleep Solutions®, Inc. (SSI), ...esting and evaluation of sleep-disordered breathin....D., as its chief executive officer. Hassett was ...ng its growth from a $250 million healthcare holdi...total population health, and its subsequent sale f...
(Date:12/1/2009)... 1 Siemens Hearing Instruments, I...al manufacturer of hearing instruments, announced ...nal,s Sound Beginnings program. The alliance will ... of the renewed partnership, Siemens is expanding ...ng instruments to both children and young adults, ...
Breaking Medicine Technology:CEL-SCI Retains Global Contract Research Organization to Manage Upcoming Phase III Clinical Trial for Its Cancer Drug Multikine 2CEL-SCI Retains Global Contract Research Organization to Manage Upcoming Phase III Clinical Trial for Its Cancer Drug Multikine 3Sleep Solutions, Inc. Names Richard Hassett, M.D., New CEO 2Sleep Solutions, Inc. Names Richard Hassett, M.D., New CEO 3Siemens Hearing Instruments Renews Quota Partnership to Give the Gift of Hearing to Children and Young Adults in Need 2Siemens Hearing Instruments Renews Quota Partnership to Give the Gift of Hearing to Children and Young Adults in Need 3Long Term Data Updates Show Further Extensions of Survival and Delays in Recurrence in Brain Cancer Patients Who Received DCVax 28R 29 Brain 5631 1Long Term Data Updates Show Further Extensions of Survival and Delays in Recurrence in Brain Cancer Patients Who Received DCVax 28R 29 Brain 5631 2Long Term Data Updates Show Further Extensions of Survival and Delays in Recurrence in Brain Cancer Patients Who Received DCVax 28R 29 Brain 5631 3Long Term Data Updates Show Further Extensions of Survival and Delays in Recurrence in Brain Cancer Patients Who Received DCVax 28R 29 Brain 5631 4Long Term Data Updates Show Further Extensions of Survival and Delays in Recurrence in Brain Cancer Patients Who Received DCVax 28R 29 Brain 5631 5Shire Targets Fourth Quarter Filing of BLA for REPLAGAL 28R 29 for Fabry Disease With U S FDA 5629 1Shire Targets Fourth Quarter Filing of BLA for REPLAGAL 28R 29 for Fabry Disease With U S FDA 5629 2Shire Targets Fourth Quarter Filing of BLA for REPLAGAL 28R 29 for Fabry Disease With U S FDA 5629 3Shire Targets Fourth Quarter Filing of BLA for REPLAGAL 28R 29 for Fabry Disease With U S FDA 5629 4Vestara Joins National Health Organization Practice Greenhealth to Further Support Environmental Practices 59887 1Vestara Joins National Health Organization Practice Greenhealth to Further Support Environmental Practices 59887 2Vestara Joins National Health Organization Practice Greenhealth to Further Support Environmental Practices 59887 3
...June 21, 2007 /PRNewswire-FirstCall/ - Biotech,Hol... has given,Biotech,s "Sucanon" diabetes drug its s...in the May-June 2007 issue of Diabetes,Hoy, the Di...e for,doctors and other health professionals. , Th...to Cepeda,Gonzalez, Medical Director of the Specia...
... to Indicate that Early Use of Estrogen May be,Car...-USNewswire/ -- A new analysis,of Women,s Health I...l of Medicine, shows significant reduction in calc... therapy (HT) compared,with women taking a placebo...estrogen therapy and coronary artery calcium,(CAC)...
Other Medicine Technology:Diabetes drug supported by Mexican Diabetes Federation 2Diabetes drug supported by Mexican Diabetes Federation 3Arterial Plaque Significantly Reduced in Women Age 50-59 Taking,Hormones, Says New Analysis of Women's Health Initiative Data 2Arterial Plaque Significantly Reduced in Women Age 50-59 Taking,Hormones, Says New Analysis of Women's Health Initiative Data 3
ZapICD
ZapBill Anesthesia
WardWatch v3.1.1
MedCalc 3000
Medicine Products: